^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD19 inhibitor

    Related drugs:
    2d
    A041703: Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=84, Recruiting, National Cancer Institute (NCI) | N=64 --> 84
    Enrollment change
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    Iclusig (ponatinib) • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
    2d
    Clinical strategies for leukemia management: Recommendations from the Bridging the Gaps in Hematology Oncology Consensus Conference 2025. (PubMed, Leuk Res)
    For ALL, recommendations highlighted avoiding transplant in most Philadelphia chromosome-positive patients achieving minimal residual disease (MRD)-negativity by noting the high relapse risk with certain IKZF1, CDKN2A/B, and PAX5 aberrations, and administering blinatumomab regardless of MRD status in Philadelphia chromosome-positive and -negative ALL...Future directions include refining treatment sequencing, improving outcomes for high-risk subtypes, evaluating the role of HSCT in the era of novel therapies, and standardizing MRD assessment. This consensus report provides valuable expert insights to inform clinical practice and guide future research in leukemia.
    Journal
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • IKZF1 (IKAROS Family Zinc Finger 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PAX5 (Paired Box 5)
    |
    TP53 mutation
    |
    Blincyto (blinatumomab) • Vyxeos (cytarabine/daunorubicin liposomal formulation)
    4d
    Impact of measurable residual disease on outcomes using a modified DFCI protocol for adults with BCR-ABL negative acute lymphoblastic leukemia. (PubMed, Leuk Res)
    In conclusion, MRD is a significant predictor of outcomes with DFCI. DFS and OS are high in MRD negative patients, without the use of blinatumomab.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    Blincyto (blinatumomab)
    4d
    A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov)
    P1, N=30, Recruiting, Hinge Bio
    New P1 trial
    4d
    Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New trial • IO biomarker
    |
    ABL1 (ABL proto-oncogene 1) • BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • cytarabine • Blincyto (blinatumomab) • Nailike (olverembatinib)
    9d
    SOUNDTRACK-D2: AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL (clinicaltrials.gov)
    P3, N=420, Recruiting, AstraZeneca
    Trial initiation date
    |
    doxorubicin hydrochloride • cyclophosphamide • surovatamig (AZD0486)
    10d
    A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101) (clinicaltrials.gov)
    P1, N=100, Recruiting, MSD R&D (China) Co., Ltd. | Trial primary completion date: Mar 2027 --> Sep 2028
    Trial primary completion date
    |
    IL2 (Interleukin 2)
    |
    CD19 positive
    12d
    International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) (clinicaltrials.gov)
    P3, N=750, Not yet recruiting, Charite University, Berlin, Germany
    New P3 trial
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    |
    Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
    12d
    Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, ImmunityBio, Inc.
    New P2 trial
    |
    Rituxan (rituximab) • Anktiva (nogapendekin alfa inbakicept-pmln) • CD19.t-haNK
    12d
    ELEVATE-1: A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD) (clinicaltrials.gov)
    P1, N=54, Recruiting, GlaxoSmithKline | Not yet recruiting --> Recruiting
    Enrollment open
    |
    GSK5926371
    12d
    Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2028 --> May 2026 | Trial primary completion date: Jun 2027 --> May 2026
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    PIT565
    13d
    Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=20, Recruiting, ImmunityBio, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • Anktiva (nogapendekin alfa inbakicept-pmln) • CD19.t-haNK